Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

E Pauliat; M Onken; C Weber-Schoendorfer; V Rousson; MC Addor; D Baud; M Theaudin; O Diav-Citrin; J Cottin; M. Antonieta Agusti Escasany; V Rollason; YC Kaplan; D Kennedy; M Kadioglu; LE Rothuizen; F Livio; T Buclin; A Panchaud; U Winterfeld

doi:10.1177/1352458520929628

Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

E Pauliat^*, M Onken, C Weber-Schoendorfer, V Rousson, MC Addor, D Baud , M Theaudin, O Diav-Citrin, J Cottin, M. Antonieta Agusti Escasany, V Rollason, YC Kaplan, D Kennedy, M Kadioglu, LE Rothuizen , F Livio, T Buclin, A Panchaud, U Winterfeld^*

^*Autor corresponent d’aquest treball

Departament de Farmacologia, de Terapèutica i de Toxicologia

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

19 Cites (Scopus)

Resum

This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

Idioma original	Anglès
Pàgines (de-a)	475-478
Nombre de pàgines	4
Revista	Multiple Sclerosis Journal
Volum	27
Número	3
DOIs	https://doi.org/10.1177/1352458520929628
Estat de la publicació	Publicada - de març 2021

Accés al document

10.1177/1352458520929628

Com citar-ho

Pauliat, E., Onken, M., Weber-Schoendorfer, C., Rousson, V., Addor, MC., Baud , D., Theaudin, M., Diav-Citrin, O., Cottin, J., Agusti Escasany, M. A., Rollason, V., Kaplan, YC., Kennedy, D., Kadioglu, M., Rothuizen , LE., Livio, F., Buclin, T., Panchaud, A., & Winterfeld, U. (2021). Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Multiple Sclerosis Journal, 27(3), 475-478. https://doi.org/10.1177/1352458520929628

@article{80430cd76dd84d5ea8e21faf6fb34fca,

title = "Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.",

abstract = "This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.",

author = "E Pauliat and M Onken and C Weber-Schoendorfer and V Rousson and MC Addor and D Baud and M Theaudin and O Diav-Citrin and J Cottin and {Agusti Escasany}, {M. Antonieta} and V Rollason and YC Kaplan and D Kennedy and M Kadioglu and LE Rothuizen and F Livio and T Buclin and A Panchaud and U Winterfeld",

year = "2021",

month = mar,

doi = "10.1177/1352458520929628",

language = "English",

volume = "27",

pages = "475--478",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "3",

}

Pauliat, E, Onken, M, Weber-Schoendorfer, C, Rousson, V, Addor, MC, Baud , D, Theaudin, M, Diav-Citrin, O, Cottin, J, Agusti Escasany, MA, Rollason, V, Kaplan, YC, Kennedy, D, Kadioglu, M, Rothuizen , LE, Livio, F, Buclin, T, Panchaud, A & Winterfeld, U 2021, 'Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.', Multiple Sclerosis Journal, vol. 27, núm. 3, pàg. 475-478. https://doi.org/10.1177/1352458520929628

TY - JOUR

T1 - Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

AU - Pauliat, E

AU - Onken, M

AU - Weber-Schoendorfer, C

AU - Rousson, V

AU - Addor, MC

AU - Baud , D

AU - Theaudin, M

AU - Diav-Citrin, O

AU - Cottin, J

AU - Agusti Escasany, M. Antonieta

AU - Rollason, V

AU - Kaplan, YC

AU - Kennedy, D

AU - Kadioglu, M

AU - Rothuizen , LE

AU - Livio, F

AU - Buclin, T

AU - Panchaud, A

AU - Winterfeld, U

PY - 2021/3

Y1 - 2021/3

N2 - This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

AB - This prospective multicentre cohort study investigated pregnancy outcomes after fingolimod use for multiple sclerosis during pregnancy. Pregnancy outcomes of 63 fingolimod and 62 interferon-β-exposed pregnancies were compared. Rates of major congenital anomalies (MCA) were 4.8% (2/42) in the fingolimod group versus 2.3% (1/44) in the interferon-β group (odds ratio, 2.2; 95% confidence interval, 0.2–24.6). The adjusted hazard ratio for spontaneous abortion in fingolimod versus interferon-β-exposed pregnancies was 0.6 (95% confidence interval, 0.2–1.8). Further studies are needed to definitely rule out a moderately increased MCA risk after fingolimod exposure during pregnancy.

U2 - 10.1177/1352458520929628

DO - 10.1177/1352458520929628

M3 - Article

SN - 1352-4585

VL - 27

SP - 475

EP - 478

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 3

ER -

Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study.

Resum

Accés al document

Fingerprint

Com citar-ho